These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 23452174)
1. Cinacalcet hydrochloride for the treatment of hyperparathyroidism. Verheyen N; Pilz S; Eller K; Kienreich K; Fahrleitner-Pammer A; Pieske B; Ritz E; Tomaschitz A Expert Opin Pharmacother; 2013 Apr; 14(6):793-806. PubMed ID: 23452174 [TBL] [Abstract][Full Text] [Related]
2. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients. Shireman TI; Almehmi A; Wetmore JB; Lu J; Pregenzer M; Quarles LD Am J Kidney Dis; 2010 Dec; 56(6):1108-16. PubMed ID: 20951487 [TBL] [Abstract][Full Text] [Related]
3. New strategies for the treatment of hyperparathyroidism incorporating calcimimetics. de Francisco AL Expert Opin Pharmacother; 2008 Apr; 9(5):795-811. PubMed ID: 18345956 [TBL] [Abstract][Full Text] [Related]
4. A cost-utility analysis of cinacalcet in secondary hyperparathyroidism in five European countries. Iannazzo S; Carsi M; Chiroli S Appl Health Econ Health Policy; 2012 Mar; 10(2):127-38. PubMed ID: 22268372 [TBL] [Abstract][Full Text] [Related]
5. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism. Dong BJ Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445 [TBL] [Abstract][Full Text] [Related]
6. Cinacalcet for secondary hyperparathyroidism: from improved mineral levels to improved mortality? Vervloet MG; du Buf-Vereijken PW; Potter van Loon BJ; Manamley N; Reichert LJ; Smak Gregoor PJ Neth J Med; 2013 Sep; 71(7):348-54. PubMed ID: 24038560 [TBL] [Abstract][Full Text] [Related]
7. Clinical utilization of cinacalcet in hypercalcemic conditions. Messa P; Alfieri C; Brezzi B Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):517-28. PubMed ID: 21361849 [TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis. Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan. Komaba H; Moriwaki K; Goto S; Yamada S; Taniguchi M; Kakuta T; Kamae I; Fukagawa M Am J Kidney Dis; 2012 Aug; 60(2):262-71. PubMed ID: 22445709 [TBL] [Abstract][Full Text] [Related]
10. The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial. Parfrey PS; Chertow GM; Block GA; Correa-Rotter R; Drüeke TB; Floege J; Herzog CA; London GM; Mahaffey KW; Moe SM; Wheeler DC; Dehmel B; Trotman ML; Modafferi DM; Goodman WG J Clin Endocrinol Metab; 2013 Dec; 98(12):4834-44. PubMed ID: 24108314 [TBL] [Abstract][Full Text] [Related]
11. Molecular and Clinical Aspects of the Target Therapy with the Calcimimetic Cinacalcet in the Treatment of Parathyroid Tumors. Mingione A; Verdelli C; Terranegra A; Soldati L; Corbetta S Curr Cancer Drug Targets; 2015; 15(7):563-74. PubMed ID: 26033088 [TBL] [Abstract][Full Text] [Related]
12. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. Palmer SC; Nistor I; Craig JC; Pellegrini F; Messa P; Tonelli M; Covic A; Strippoli GF PLoS Med; 2013; 10(4):e1001436. PubMed ID: 23637579 [TBL] [Abstract][Full Text] [Related]
13. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis. Narayan R; Perkins RM; Berbano EP; Yuan CM; Neff RT; Sawyers ES; Yeo FE; Vidal-Trecan GM; Abbott KC Am J Kidney Dis; 2007 Jun; 49(6):801-13. PubMed ID: 17533023 [TBL] [Abstract][Full Text] [Related]
14. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease. Torres PU J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031 [TBL] [Abstract][Full Text] [Related]
15. Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1. Del Prete M; Marotta V; Ramundo V; Marciello F; Di Sarno A; Esposito R; Carratù AC; De Luca Di Roseto C; Di Somma C; Colao A; Faggiano A Minerva Endocrinol; 2013 Dec; 38(4):389-94. PubMed ID: 24285106 [TBL] [Abstract][Full Text] [Related]
16. Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Fukagawa M; Shimazaki R; Akizawa T; Kidney Int; 2018 Oct; 94(4):818-825. PubMed ID: 30049473 [TBL] [Abstract][Full Text] [Related]
17. Cinacalcet for the treatment of primary hyperparathyroidism. Dillon ML; Frazee LA Am J Ther; 2011 Jul; 18(4):313-22. PubMed ID: 20228675 [TBL] [Abstract][Full Text] [Related]
18. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Tentori F; Wang M; Bieber BA; Karaboyas A; Li Y; Jacobson SH; Andreucci VE; Fukagawa M; Frimat L; Mendelssohn DC; Port FK; Pisoni RL; Robinson BM Clin J Am Soc Nephrol; 2015 Jan; 10(1):98-109. PubMed ID: 25516917 [TBL] [Abstract][Full Text] [Related]
19. Cinacalcet in the treatment of hypercalcaemia and control of hyperparathyroidism due to ectopic parathyroid glands. Picazo Sánchez M; Cuxart Pérez M; Sans Lorman R; Sardà Borroy C Nefrologia; 2011; 31(1):126-7. PubMed ID: 21270934 [No Abstract] [Full Text] [Related]
20. Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States. Boer R; Lalla AM; Belozeroff V J Med Econ; 2012; 15(3):509-20. PubMed ID: 22313328 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]